A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Trial Profile

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Telisotuzumab vedotin (Primary) ; Bevacizumab; Carboplatin; Cetuximab; Erlotinib; Nivolumab
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 21 Nov 2017 Planned End Date changed from 29 Jan 2021 to 11 Nov 2019.
    • 18 Oct 2017 Results (n=16, data cut off: April 26, 2017) presented at the 18th World Conference on Lung Cancer
    • 01 Aug 2017 Planned End Date changed from 11 Oct 2018 to 29 Jan 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top